Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Clinical trial NCT05611229 · COMPLETED

Trial details

NCT number: NCT05611229
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

Metastatic Melanoma

Start date: 2020-06-16
Primary completion: 2021-12-03
Enrollment: 1975

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.